 |
|
Comparison of N-Terminal Pro–B-Natriuretic Peptide, C-Reactive Protein, and Creatinine Clearance for Prognosis in Patients With Known Coronary Heart Disease
Dietrich Rothenbacher, MD, MPH;
Wolfgang Koenig, MD;
Hermann Brenner, MD, MPH
Arch Intern Med. 2006;166:2455-2460.
Background The purpose of this study was to investigate the prognostic role of N-terminal pro–B-natriuretic peptide (NT-proBNP) serum level compared with C-reactive protein (CRP) level and creatinine clearance (CrCl) for the subsequent risk of cardiovascular events in a large cohort of patients with stable coronary heart disease (CHD).
Methods Serum concentrations of NT-proBNP and CRP and CrCl were measured at baseline in a cohort of 1051 patients aged 30 to 70 years with CHD. The Cox proportional hazards model was used to determine the prognostic value of NT-proBNP, CRP, and CrCl on a combined cardiovascular disease (CVD) end point (fatal and nonfatal myocardial infarction and stroke).
Results During follow-up (mean of 48.7 months), 95 patients (9.0%) experienced a secondary CVD event. Patients in the top quartile of the NT-proBNP distribution at baseline had a hazard ratio (HR) of 3.34 (95% confidence interval [CI], 1.74-6.45) for subsequent secondary CVD events compared with those in the bottom quartile (P for trend <.001) after controlling for age, sex, smoking status, history of diabetes mellitus, initial management of CHD, rehabilitation clinic, high-density lipoprotein cholesterol, low-density lipoprotein cholesterol, and treatment with lipid-lowering drugs. For CRP, the corresponding HR was 1.76 (95% CI, 0.96-3.24) (P value for trend, .06). Patients with CrCl levels lower than 60 mL/min had an HR of 2.39 (95% CI, 1.06-5.40) compared with patients with a CrCl of 90 mL/min or higher (P for trend, .002). If all 3 markers were included simultaneously in 1 model, NT-proBNP still showed predictive ability for recurrent CVD events.
Conclusion N-terminal proBNP may be a clinically useful marker weeks after an acute coronary event and may provide complementary prognostic information to established risk determinants.
Author Affiliations: Department of Clinical Epidemiology and Aging Research, German Cancer Research Center, Heidelberg, Germany (Drs Rothenbacher and Brenner); and Department of Internal Medicine II–Cardiology, University of Ulm Medical Center, Ulm, Germany (Dr Koenig).
RELATED ARTICLE
The Latest and Greatest New Biomarkers: Which Ones Should We Measure for Risk Prediction in Our Practice?
James A. de Lemos
Arch Intern Med. 2006;166(22):2428-2430.
EXTRACT
| FULL TEXT
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
Atherogenic dyslipidaemia but not total- and high-molecular weight adiponectin are associated with the prognostic outcome in patients with coronary heart disease
von Eynatten et al.
Eur Heart J 2008;29:1307-1315.
ABSTRACT
| FULL TEXT
Glomerular Filtration Rate and N-Terminal Pro-Brain Natriuretic Peptide as Predictors of Cardiovascular Mortality in Vascular Patients
Shadman et al.
J Am Coll Cardiol 2007;49:2172-2181.
ABSTRACT
| FULL TEXT
Newer Biomarkers Add Little in Predicting Death, CV Events
JWatch General 2007;2007:2-2.
FULL TEXT
The Latest and Greatest New Biomarkers: Which Ones Should We Measure for Risk Prediction in Our Practice?
de Lemos
Arch Intern Med 2006;166:2428-2430.
FULL TEXT
|
